Related Experiment Video

Updated: May 1, 2026

A 3D Organotypic Melanoma Spheroid Skin Model
08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

18.1K

Metastatic melanoma: optimizing outcomes by managing dermatologic toxicities associated with novel therapies

Joel Claveau1, Vincent Ho, Teresa Petrella

  • 1Centre Hospitalier Universitaire de Québec, Hôtel-Dieu de Québec; Melanoma and Skin Cancer Clinic, Quebec City, QC, Canada; Department of Dermatologic Oncology, British Columbia Cancer Agency, and Department of Dermatology and Science, University of British Columbia, Vancouver, BC, Canada; Division of Medical Oncology/Hematology, Odette Cancer Centre, Toronto, ON, Canada.

Skin Therapy Letter
|April 18, 2014
PubMed

Insights

New BRAF inhibitors and immune modulators offer survival benefits for metastatic melanoma patients. Effective management of unique adverse events (AEs) is crucial for optimizing outcomes with these advanced therapies.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Metastatic melanoma historically has a poor prognosis and limited treatment options.
  • Recent advancements have introduced novel therapeutic classes, including BRAF inhibitors and immune modulators.

Purpose of the Study:

  • To review the clinical benefits and unique adverse events (AEs) associated with new metastatic melanoma treatments.
  • To emphasize the importance of managing treatment-related toxicities for optimal patient outcomes.

Main Methods:

  • Literature review of recent clinical trials and therapeutic strategies in metastatic melanoma.
  • Analysis of adverse event profiles for BRAF inhibitors and immune modulators.

Main Results:

  • BRAF inhibitors and immune modulators have demonstrated significant overall survival benefits.
  • These agents are associated with unique adverse events, ranging from mild to severe.
  • Effective management strategies are essential for mitigating treatment-related toxicities.

Conclusions:

  • The treatment landscape for metastatic melanoma is rapidly evolving with new therapeutic options.
  • Understanding and proactively managing the toxicities of current therapies are critical for improving patient care and outcomes.

More Related Videos

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

2.3K
Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma09:52

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Published on: January 25, 2015

12.8K

Related Concept Videos

Skin Cancer01:30

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
5.2K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.5K
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
429
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K